ASST PAPA GIOVANNI XXIII; Ematologia
About ASST PAPA GIOVANNI XXIII; Ematologia
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Gruppo Italiano Malattie EMatologiche dell'Adulto
11
Hoffmann-La Roche
10
Gruppo Italiano Trapianto di Midollo Osseo
8
Northern Italy Leukemia Group
4
Celgene
2
Fondazione per la Ricerca Ospedale Maggiore
2
A.O. Ospedale Papa Giovanni XXIII
1
Fondazione Italiana Linfomi ONLUS
1
Sigma Tau Research Switzerland SA
1
Clinical Trials at ASST PAPA GIOVANNI XXIII; Ematologia
During the past decade, ASST PAPA GIOVANNI XXIII; Ematologia conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 5 clinical trials were completed, i.e. on
average, 22.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
2005-08-01
2009-08-01
Terminated
25
A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia
2000-05-01
2007-10-01
Completed
581
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
2004-10-01
2007-12-01
Completed
25
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
2004-01-19
2011-07-21
Completed
234
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
2002-11-01
2014-06-01
Completed
182
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
2011-07-06
2021-07-30
Completed
1,401
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "ASST PAPA GIOVANNI XXIII; Ematologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 11 trials, followed by "Hoffmann-La Roche" with 10 trials
sponsored, "Gruppo Italiano Trapianto di Midollo Osseo" with 8 trials sponsored, "Northern Italy Leukemia Group" with 4 trials sponsored and "Celgene"
with 4 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "ASST PAPA GIOVANNI XXIII; Ematologia"
#1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "AOP Orphan Pharmaceuticals AG" with 1 trials as a collaborator, "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator and "Institute of Cancer Research, United Kingdom" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were
collaborators in the rest 10 trials.
Clinical Trials Conditions at ASST PAPA GIOVANNI XXIII; Ematologia
According to Clinical.Site data, the most researched conditions in "ASST PAPA GIOVANNI XXIII; Ematologia" are
"Acute Myeloid Leukemia" (3 trials), "Hematologic Diseases" (3 trials), "Lymphoma, Non-Hodgkin" (3 trials), "Acute Lymphoblastic Leukemia" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "ASST PAPA GIOVANNI XXIII; Ematologia" in a lesser frequency.
Clinical Trials Intervention Types at ASST PAPA GIOVANNI XXIII; Ematologia
Most popular intervention types in "ASST PAPA GIOVANNI XXIII; Ematologia" are "Drug" (29 trials), "Other" (4 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.
The name of intervention was led by "Tocilizumab" (5 trials), "Glofitamab" (4 trials), "Obinutuzumab" (4 trials), "Cyclophosphamide" (2 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.
Clinical Trials Genders at ASST PAPA GIOVANNI XXIII; Ematologia
The vast majority of trials in "ASST PAPA GIOVANNI XXIII; Ematologia" are
40 trials for "All" genders.
Clinical Trials Status at ASST PAPA GIOVANNI XXIII; Ematologia
Currently, there are NaN active trials in "ASST PAPA GIOVANNI XXIII; Ematologia".
undefined are not yet recruiting,
10 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 22 completed trials in ASST PAPA GIOVANNI XXIII; Ematologia,
1 suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in ASST PAPA GIOVANNI XXIII; Ematologia, 7 "Phase 1"
clinical trials were conducted, 17 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".